Journal article

Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity

Daniel V Brown, Gulay Filiz, Paul M Daniel, Frederic Hollande, Sebastian Dworkin, Stephanie Amiridis, Nicole Kountouri, Wayne Ng, Andrew P Morokoff, Theo Mantamadiotis



Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and drug resistance following therapy. Genome-wide profiling has revealed the existence of distinct GBM molecular subtypes that respond differently to aggressive therapies. Despite this, molecular subtype does not predict recurrence or drug resistance and overall survival is similar across subtypes. One of the key features contributing to tumor recurrence and resistance to therapy is proposed to be an underlying subpopulation of resistant glioma stem cells (GSC). CD133 expression has been used as a marker of GSCs, however recent evidence suggests the relationship between CD133 expression, GSCs an..

View full abstract


Awarded by Department of Pathology at University of Melbourne (Pathology Funds)

Awarded by CASS Foundation

Awarded by Pathology Funds

Funding Acknowledgements

This study was supported by funds from the Department of Pathology at University of Melbourne (Pathology Funds 531-42) to DVB, PMD and GF. This study was also supported by a CASS Foundation grant #6236. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.We thank Josh Kie, Daniel Blashki, Vanta Jameson and Desiree Anthony for flow cytometry assistance. We thank the technicians at the Royal Melbourne Hospital for assisting with animal husbandry and maintenance of colonies. We extend our gratitude to the donors of the tumor derived PDGC lines. Prof Paul Waring for scientific discussions and financial support (Pathology Funds 531-42) of DVB PMD, GF and the Cell Signalling Laboratory.